Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTME: TIL Therapy with Low-dose IFN-alpha and Nivolumab in Melanoma
NCT03638375Phase 2Active, not recruiting
- Sponsor
- Leiden University
- Start
- Jul 2018
- Primary completion
- Nov 2025
- Modality
- Cell Therapies, Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous tumor-infiltrating lymphocytes, interferon alfa in melanoma, sponsored by Leiden University. Started Jul 2018; status: active, not recruiting.
02
Drugs
autologous tumor-infiltrating lymphocytesinterferon alfa
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03638375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03638375.